The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences, makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the ...

Abbott Laboratories saw a big jump in demand for its diabetes products in the first quarter, which helped the medical-device company extend its long streak of earnings beats and propelled the stock to ...

Novo Nordisk and Eli Lilly have generated billions of dollars in revenue selling weight loss drugs. Abbott Labs is launching a complementary product for those on the weight loss path. Drugmakers Novo ...

Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This ...

Abbott Laboratories is scheduled to report fourth-quarter earnings before the market opens Thursday. Here is what you need to know: NET INCOME: The healthcare-products maker is projected to post a ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

Abbott has delivered share price performance and passive income to investors for years. The company is diversified across healthcare businesses and sells many leading products. Abbott's performance ...

This company has delivered earnings and dividend growth over time. Abbott’s innovation and a new acquisition could spur more growth in the years to come. 10 stocks we like better than Abbott ...